Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Greg Alexander, who owns 75% of Conifer Management LLP reportedly manages the personal wealth of Charlie Munger. His fund is massively concentrated in just 10 stocks. And yet he is a 7.7% shareholder of AGL having bought in December 23
This all seems to be going the right way and I believe its only a matter of time before we can all see some strong returns from this stock!
Probably TwoGood2Die building up their stake further.
Hmm.
Sounds very sensible EC.
If he starts to make material sales at last - happy days. One can live in hope but once bitten - twice shy. And here we have been bitten multiple times.
Bantham.
As I said clearly Mr Newland and the board see the massive potential here for this CellKeep™ slide or they would not have applied for patents in the EU and USA. A simple, by the looks cheap to make plastic device which is far gentler on the cells that end up on the microscope slide. Not only that, but the cells are also concentrated in a smaller area. So, any cells are far less likely to get damaged/killed and are in a smaller area so easier to find! Plus, it says using the device should save on the cost of antibodies as less are needed. Three very positive points for adopting the use of this device! The RNS says the device with the "Portrait Plus CTC staining kit" and Mr Newland says they might offer it separately. Offering it separately would be potentially handing the advantage the device gives their Parsortix machine to some competitors. Having said that competing methods to capture circulating tumour cells are complicated and come with very specific instructions on how to use the particular system. Unlikely to say "then use an Angle Plc CellKeep™ slide” to obtain the cells for viewing with the microscope! I think Angle Plc should immediately offer this device Worldwide through distributors. It could and up as a standard device for use when the cells to be viewed are liable to get damaged during the normal centrifuge process. Sales of potentially tens of thousands world-wide.
https://www.lse.co.uk/rns/AGL/us-and-eu-patents-for-innovative-cellkeep8482-slide-3s3v2c8b8y6u32u.html
All IMHO.
Exactly on point:
1. Newland has to deliver some meaningful sales, and stop hyping the ones he's got. Eisei being a case in pouint where he trailed it ad nauseam and result was 250k pilot .....
2. So we get a patent filing but no update on the Solaris prostate clinical study agreement. Newland promised the results would be ready by end of "023....and 4 months later absolute silence. it is this sort of behaviour that has cost investors huge sums, cratered confidence, and led a number of institutions to the conclusion that he cannot be trusted to tell the truth
Which judging by the lack of commercial sales of Parsortix to date is rather perplexing with FDA approval for breast cancer testing you would have thought labs would be falling over themselves to acquire Parsortix testing machines which to date appears not to be the case!
Can jam be made from 🥕's I wonder!
Morning EC
I agree - it appears to be good progress in capabilities.
But the issue - that even you will admit - is that Newland has offered lashings of jam tomorrow dozens of times before. And he has never delivered material revenues. So i think what you saw yesterday is that even the rampers have lost interest - the spike / drop history is so undeniable now that people don’t want to risk their cash anymore.
So all that means is - deliver some actual sales Mr Newland.
Bantham.
Clearly Mr Newland and the board see the massive potential here for this CellKeep™ slide or they would not have applied for patents in the EU and USA. Having had more a think it could be a very major part of Angles revenues. In fact Worldwide something like this cheap to make plastic "slide" could end up being the biggest money maker for Angle. This device, which obviously is far more gentle on the cells it captures on the slides so they are less damaged, and as the RNS says concentrates the CTCs into a smaller area on the slide (making processing cheaper) could easily become extremely popular............. WORLD WIDE. That is a big market. Sales could in time be in the tens of thousands, or even more.
As ANGLE Chief Scientific Officer, Karen Miller said "This technology is a significant advancement over current standards for CTCs and has the potential to capture other cell types from body fluids such as blood, urine or cerebrospinal fluid, for subsequent analysis".....................................................................................Holy **it.
MUCH more significant than the 4.12% gain today which is a total joke.
All IMHO.
Nice to see some progress EC. Agreed.
But he needs to sell some! That is where he needs to show a bit of progress.
Seems that even the rampers can’t be bothered to react to Newland anymore. Interesting.
Angle have clearly put a huge amount of effort creating this "Portrait Plus CTC staining kit" which includes the innovative CellKeep™ slide referred to in todays RNS. As Andrew explains the kit standardises the stains used, gives the stains greater shelf life (as they are in the form of a dissolvable tablet) and uses the now patented CellKeep™ slide to reduce circulating tumour cell (CTC) loss !!! As he explains the patented CellKeep™ slide makes the Parsortix system far more efficient compared to using the industry standard way which can damage and kill the CTC's. I don't think it's possible to get a better CTC sample (99% alive and undamaged) for subsequent analysis.
https://www.youtube.com/watch?v=hxu_XmeIpDA
All IMHO.
Thumbs up from me
Agree Rick and thanks Bermuda for the link. Not seeing any real gains today is very odd but the market is clapped out so I guess brilliant news is just wasted on AIM? I am watching out for another hot RNS that might kick start a rise before results.
Like this?
Someone needs to sound the bugle and shout out its news as this is a ridiculous rise on a quite brilliant RNS.
Proactive interview with Andrew Newland highlights the work involved
https://www.youtube.com/watch?v=hxu_XmeIpDA
========================
Also very important about the RNS of 4th Jan "Angle PLC Breakthrough clinical results (5877Y)", see link below.:-
Companies doing Cancer drug trials will NOW want standard blood CtDna analysis ***AND*** Circulating Tumour Cell analysis for even more information on how their extremenly expensive drug trials are doing etc. OF COURSE they will want the maximum information available in order to log for the future and evaluate how their drug is performing!!! The IS A NO BRAINER.
And that is just one of Angle's offerings................................................
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
All IMHO.
Proactive interview with Andrew Newland highlights the work involved
https://www.youtube.com/watch?v=hxu_XmeIpDA
Parsortix still works. It always did...
Huge pat on the back to the scientists at Angle
TwoGood2Die.
Let's discuss given FDA approval for breast cancer testing was granted a while back why global sales of the Parsortix machine hasn't taken off any suggestions?
===================================
How do you know sales of the Parsortix machine @ $50,000 to $70,000 have not taken off. Do we need to add insider trading to the list of illegal things you do? LOL! The results are due. We will see if:-
Companies doing Cancer drug trials NOW want standard blood CtDna analysis ***AND*** Circulating Tumour Cell analysis for even more information on how their extremenly expensive drug trials are doing etc. OF COURSE they will want the maximum information available in order to log for the future and evaluate how their drug is performing!!! The IS A NO BRAINER.
And that is just one of Angle's offerings................................................
TwoGood2Die.
Let's discuss given FDA approval for breast cancer testing was granted a while back why global sales of the Parsortix machine hasn't taken off any suggestions?
===================================
How do you know sales of the Parsortix machine @ $50,000 to $70,000 have not taken off. Do we need to add insider trading to the list of illegal things you do? The bottom line I think you will find is the CtD